Abstract
The outcomes of patients with la/mUC are poor; however, systemic treatments (STs) including chemotherapy sequenced by maintenance immunotherapy (IO) are available to extend survival. First-line (1L) treatment patterns and reasons for no receipt of ST (NST) are not well known. We aimed to characterize 1L treatment patterns, NST, attrition rates across line of therapy, and factors influencing treatment selection for patients with la/mUC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
